The discovery focuses on disrupting the function of a certain protein complex that cancer cells, including leukemia cells, ...

A GENETIC variant, the BIM deletion polymorphism (BDP), has been identified by researchers to significantly enhance leukemia ...

Researchers from the Tumor Profiler consortium have combined single-cell multi-omics and functional profiling for 21 AML ...

For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

T cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). T-ALL, known for its challenging ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Of these, chronic myeloid leukemia (CML) is a subtype that primarily affects the bone marrow, which produces blood cells. The Duke-NUS scientists, in collaboration with their partners, including ...

The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...

The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.